

MEDICAL POLICY

POLICY TITLE	HEMATOPOIETIC CELL TRANSPLANTATION FOR WALDENSTROM MACROGLOBULINEMIA
POLICY NUMBER	MP 9.046

CLINICAL BENEFIT	<input type="checkbox"/> MINIMIZE SAFETY RISK OR CONCERN. <input checked="" type="checkbox"/> MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. <input type="checkbox"/> ASSURE APPROPRIATE LEVEL OF CARE. <input type="checkbox"/> ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. <input checked="" type="checkbox"/> ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. <input type="checkbox"/> ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
Effective Date:	7/1/2025

[POLICY RATIONALE](#)
[DISCLAIMER](#)
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)
[DEFINITIONS](#)
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)
[BENEFIT VARIATIONS](#)
[REFERENCES](#)

I. POLICY

Autologous hematopoietic cell transplantation may be considered **medically necessary** as salvage therapy of chemosensitive Waldenstrom macroglobulinemia.

Allogeneic hematopoietic cell transplantation is considered **investigational** to treat Waldenstrom macroglobulinemia. There is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

Cross-References:

MP 9.042 Hematopoietic Cell Transplantation for Non-Hodgkin Lymphomas
MP 9.001 Placental/Umbilical Cord Blood as a Source of Stem Cells.

II. PRODUCT VARIATIONS

[Top](#)

This policy is only applicable to certain programs and products administered by Capital BlueCross and subject to benefit variations as discussed in Section VI. Please see additional information below.

FEP PPO: Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at: <https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>.

III. DESCRIPTION/BACKGROUND

[Top](#)

Waldenström Macroglobulinemia

Waldenström macroglobulinemia (WM) is a clonal disorder of B lymphocytes that accounts for 1% to 2% of hematologic malignancies, with an estimated 1500 new cases annually in the

MEDICAL POLICY

POLICY TITLE	HEMATOPOIETIC CELL TRANSPLANTATION FOR WALDENSTROM MACROGLOBULINEMIA
POLICY NUMBER	MP 9.046

United States. Symptoms include weakness, headaches, stroke-like symptoms (confusion, loss of coordination), vision problems, excessive bleeding, unexplained weight loss, and frequent infections. The median age of WM patients is 63 to 68 years, with men comprising 55% to 70% of cases. Median survival of WM ranges from 5 to 10 years, with age, hemoglobin concentration, serum albumin level, and β_2 -microglobulin level as predictors of outcome.

The Revised European American Lymphoma and World Health Organization classification and a consensus group formed at the Second International Workshop on Waldenström's Macroglobulinemia recognize WM primarily as a lymphoplasmacytic lymphoma with an associated immunoglobulin M (IgM) monoclonal gammopathy. The definition also requires the presence of a characteristic pattern of bone marrow infiltration with small lymphocytes demonstrating plasmacytic differentiation with variable cell surface antigen expression. The Second International Workshop indicated no minimum serum concentration of IgM is necessary for a diagnosis of WM.

Treatment

The goal of therapy for patients with WM is to achieve symptomatic relief and reduce organ damage without compromising quality of life. Treatment of WM is indicated only in symptomatic patients and should not be initiated solely on the basis of serum IgM concentration. Clinical and laboratory findings that indicate the need for therapy of diagnosed WM include a hemoglobin concentration less than 10 g/dL; platelet count less than 100,000/ μ L; significant adenopathy or organomegaly; symptomatic Ig-related hyperviscosity (>50 g/L); severe neuropathy; amyloidosis; cryoglobulinemia; cold-agglutinin disease; or evidence of disease transformation.

Primary chemotherapeutic options in patients that may undergo autologous hematopoietic cell transplantation (HCT) often combine rituximab with other agents (e.g., dexamethasone, cyclophosphamide, bortezomib, bendamustine), but other agents may also be used including purine analogues (cladribine, fludarabine). Plasma exchange is indicated for acute treatment of symptomatic hyperviscosity.

Conventional Preparative Conditioning for HCT

The conventional ("classical") practice of allogeneic HCT involves administration of cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without total body irradiation at doses sufficient to destroy endogenous hematopoietic capability in the recipient. The beneficial treatment effect in this procedure is due to a combination of initial eradication of malignant cells and subsequent graft-versus-malignancy effect that develops after engraftment of allogeneic stem cells within patients' bone marrow space. While the slower graft-versus-malignancy effect is considered the potentially curative component, it may be overwhelmed by extant disease without the use of pretransplant conditioning. However, intense conditioning regimens are limited to patients who are sufficiently fit medically to tolerate substantial adverse events that include pre-engraftment opportunistic infections secondary to loss of endogenous bone marrow function and organ damage and failure caused by the cytotoxic drugs. Furthermore, in any allogeneic HCT, immune suppressant drugs are required to minimize graft rejection and graft-versus-host disease, which also increases susceptibility of the patient to opportunistic infections.

MEDICAL POLICY

POLICY TITLE	HEMATOPOIETIC CELL TRANSPLANTATION FOR WALDENSTROM MACROGLOBULINEMIA
POLICY NUMBER	MP 9.046

The success of autologous HCT is predicated on the ability of cytotoxic chemotherapy with or without radiotherapy to eradicate cancerous cells from the blood and bone marrow. This permits subsequent engraftment and repopulation of bone marrow space with presumably normal hematopoietic stem cells obtained from the patient before undergoing bone marrow ablation. As a consequence, autologous HCT is typically performed as consolidation therapy when the patient's disease is in complete remission. Patients who undergo autologous HCT are susceptible to chemotherapy-related toxicities and opportunistic infections prior to engraftment, but not graft-versus-host disease.

Reduced-Intensity Conditioning for Allogeneic HCT

Reduced-intensity conditioning (RIC) refers to the pretransplant use of lower doses or less intense regimens of cytotoxic drugs or radiotherapy than are used in conventional full-dose myeloablative conditioning treatments. The goal of RIC is to reduce disease burden but also to minimize as much as possible associated treatment-related morbidity and non-relapse mortality in the period during which the beneficial graft-versus-malignancy effect of allogeneic transplantation develops. Although the definition of RIC remains arbitrary, with numerous versions employed, all seek to balance the competing effects of non-relapse mortality and relapse due to residual disease. RIC regimens can be viewed as a continuum in effects, from nearly totally myeloablative to minimally myeloablative with lymphoablation, with intensity tailored to specific diseases and patient condition. Patients who undergo RIC with allogeneic HCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full donor chimerism, which may be supplemented with donor lymphocyte infusions to eradicate residual malignant cells. For this evidence review, the term *reduced-intensity conditioning* will refer to all conditioning regimens intended to be nonmyeloablative, as opposed to fully myeloablative (conventional) regimens.

REGULATORY STATUS

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation, title 21, parts 1270 and 1271. Hematopoietic stem cells are included in these regulations.

IV. RATIONALE

[TOP](#)

SUMMARY OF EVIDENCE

For individuals who have WM who receive HCT, the evidence includes case series. Relevant outcomes are overall survival, change in disease status, quality of life, and treatment-related mortality and morbidity. Several retrospective series have evaluated HCT for WM. Analyses of registry data have found 5-year overall survival rates of 52% after allogeneic HCT and 68.5% after autologous HCT. The total number of patients studied is small and there is a lack of published controlled studies. The evidence is insufficient to determine the effects of the technology on health outcomes.

MEDICAL POLICY

POLICY TITLE	HEMATOPOIETIC CELL TRANSPLANTATION FOR WALDENSTROM MACROGLOBULINEMIA
POLICY NUMBER	MP 9.046

Clinical input obtained from BCBSA in 2011, and national and international clinical guidelines support the use of autologous HCT as salvage therapy for patients with chemosensitive Waldenström Macroglobulinemia. Therefore, the evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

V. DEFINITIONS

[TOP](#)

NA

VI. BENEFIT VARIATIONS

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations are based on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. Members and providers should consult the member's health benefit plan for information or contact Capital Blue Cross for benefit information.

VII. DISCLAIMER

[TOP](#)

Capital Blue Cross' medical policies are developed to assist in administering a member's benefits. These medical policies do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member's plan of benefits, please contact Capital Blue Cross' Provider Services or Member Services. Capital Blue Cross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

[TOP](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Investigational; therefore, not covered:

Procedure Codes							
38205	38230	38240	38242				

Covered when medically necessary:

MEDICAL POLICY

POLICY TITLE	HEMATOPOIETIC CELL TRANSPLANTATION FOR WALDENSTROM MACROGLOBULINEMIA
POLICY NUMBER	MP 9.046

Procedure Codes							
38204	38206	38207	38208	38209	38210	38211	38212
38213	38214	38215	38232	38241	38243	S2150	

ICD-10-CM Diagnosis Code	Description
C88.00	Waldenstrom macroglobulinemia not having achieved remission
C88.01	Waldenstrom macroglobulinemia, in remission

IX. REFERENCES

[TOP](#)

1. Kyriakou C, Canals C, Sibon D, et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. *J Clin Oncol*. May 1, 2010;28(13):2227-2232. PMID 20368570
2. Cornell RF, Bachanova V, D'Souza A, et al. Allogeneic transplantation for relapsed Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma. *Biol Blood Marrow Transplant*. Jan 2017;23(1):60-66. PMID 27789362
3. Kyriakou C, Canals C, Cornelissen JJ, et al. Allogeneic stem-cell transplantation in patients with Waldenstrom macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. *J Clin Oncol*. Nov 20, 2010;28(33):4926-4934. PMID 20956626
4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma. Version 1.2023.
5. Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. *JAMA Oncol*. Sep 1, 2017;3(9):1257-1265. PMID 28056114
6. Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenstrom's Macroglobulinemia. *Blood*. Sep 8, 2016;128(10):1321-1328. PMID 27432877
7. Talaulikar D, Tam CS, Joshua D, et al. Treatment of patients with Waldenstrom macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. *Intern Med J*. Jan 2017;47(1):35-49. PMID 28076910
8. Ansell SM. Epidemiology, Pathogenesis, Clinical Manifestations, and Diagnosis of Waldenström Macroglobulinemia In: *UpToDate Online Journal* [serial online]. Waltham, MA: UpToDate; updated March 29, 2022. Literature review current through: Feb 2023
9. Ansell SM. Treatment and Prognosis of Waldenström Macroglobulinemia . *UpToDate Online Journal* [serial online]. Waltham, MA: UpToDate; updated May 26, 2022. Literature review current through: Feb 202310.

MEDICAL POLICY

POLICY TITLE	HEMATOPOIETIC CELL TRANSPLANTATION FOR WALDENSTROM MACROGLOBULINEMIA
POLICY NUMBER	MP 9.046

10. Rodríguez-Doyágüez P, Motornaya-Morozova, Martínez-Miguel P, Castillo-Torres C, Toldos-González Ó, Gil-Fernández JJ. Monoclonal gammopathy of renal significance: An atypical presentation of Waldenström's disease. *Clin Nephrol Case Stud.* 2024;12:17-21. Published 2024 Feb 8. doi:10.5414/CNCS111200
11. Sakurai M, Mori T, Uchiyama H, et al. Outcome of stem cell transplantation for Waldenström's macroglobulinemia: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group. *Ann Hematol.* 2020;99(7):1635-1642. doi:10.1007/s00277-020-04078-3
12. Treon SP, Sarosiek S, Castillo JJ. How we use Genomics and BTK-Inhibitors in the Treatment of Waldenstrom Macroglobulinemia. *Blood.* Published online January 11, 2024. doi:10.1182/blood.2022017235
13. Blue Cross Blue Shield Association Medical Policy Reference Manual. 8.01.54, Hematopoietic Cell Transplantation for Waldenstrom Magrogloulinemia. March 2021

X. POLICY HISTORY

[Top](#)

MP 9.046	02/27/2020 Consensus Review. References reviewed. No change to policy statement or coding.
	02/15/2021 Consensus Review. No change to policy statement. References updated.
	07/18/2022 Consensus Review. No change in policy statement. References updated and coding reviewed. NCCN statement added.
	03/06/2023 Consensus Review. No change in policy statement. References updated. Coding reviewed.
	02/29/2024 Consensus Review. No change in policy statement. References updated. No coding changes.
	08/16/2024 Administrative Update. New code update. Added ICD-10 codes C88.00 and C88.01. Removed ICD-10 code C88.0. Effective date 10/01/2024.
	11/20/2024 Administrative Update. Removed NCCN statement.
	01/30/2025 Consensus Review. No change in policy statement. No coding changes.

[Top](#)

Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the Blue Cross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.